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Abstract 
Background: Hereditary pancreatitis is a rare inherited form of pancreatitis, characterized by recurrent episodes of 
acute pancreatitis with early onset and/or chronic pancreatitis, and presenting brittle diabetes, composed of epi‑
sodes of nonketotic hyperglycemia and severe hypoglycemia. The existing literature regarding this form of diabetes is 
scarce. In this report, clinical features of pancreatogenic diabetes secondary to hereditary pancreatitis are presented 
along with recommendations for appropriate medical treatment.
Results: Clinical data from five patients of a family with pancreatogenic diabetes secondary to hereditary pancreatitis 
were analyzed. The average time between hereditary pancreatitis and diabetes diagnosis was 80 ± 24 months (range: 
60–180 months) with a mean age of 25.6 ± 14.7 years (range: 8–42 years), four patients used antidiabetic agents 
for 46 ± 45 months and all progressed to insulin therapy with a mean dose of 0.71 ± 0.63 IU/kg (range: 0.3–1.76 IU/
kg). The glycemic control had a high variability with average capillary blood glucose of 217.00 ± 69.44 mg/dl (range: 
145–306 mg/dl) and the average HbA1c was 9.9 ± 1.9% (range: 7.6–11.6%). No ketoacidosis episodes occurred and 
there were several episodes of hospitalization for severe hypoglycemia.
Conclusions: Diabetes mellitus secondary to hereditary pancreatitis presents with early onset, diverse clinical pres‑
entation and with extremely labile glycemic control. Diabetes treatment varies according to the presentation and 
insulin is frequently necessary for glycemic control.
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Background
Hereditary pancreatitis (HP) is a rare autosomal domi-
nant disease characterized by recurrent episodes of acute 
pancreatitis that leads to permanent chronic pancreatitis. 
Common clinical manifestations are: abdominal pain, 
disabsorptive syndrome, diabetes mellitus (DM) and pan-
creatic cancer [1].
Pancreatic inflammation results in destruction of 
pancreatic islet with loss of β-cells (insulin), α-cells 
(glucagon), δ-cells (somatostatin) and PP-cells (pancre-
atic-polypeptide) [2] that can lead to the development of 
brittle diabetes, which is characterized by extreme blood 
glucose levels fluctuations, causing hyperglycemia or 
hypoglycemia [3]. This article focuses on clinical features 
and treatment of pancreatogenic diabetes secondary to 
HP.
Methods
Clinical data from a family with confirmed molecular 
diagnosis of HP was evaluated. A retrospective analysis 
of their medical records assessed weight, age, DM dura-
tion, interval between the diagnosis of HP and DM, use 
and dose of insulin, use of oral antidiabetic medications, 
HbA1c values, episodes of severe hypoglycemia, hospi-
talization for ketoacidosis and presence of chronic com-
plications of DM. Download of data obtained through 
thirty days of self-monitoring of blood glucose using 
the Accu-Check Smart Pix Software®, was performed 
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deviation (SD) of capillary blood glucose (CBG). The 
mutation screening has been previously described [4].
The local ethics committee approved the study proto-
col (169 11-CEP), in accordance with institutional ethi-
cal standards and national research committee. Patient 
informed consent form was obtained before initiating the 
study.
Results
The study evaluated five patients from a family with HP 
secondary to N29T mutation in exon 2 of the PRSS1 
gene (Fig. 1) [4]. In 3 patients, the HP diagnosis preceded 
DM, while in 2 the opposite occurred. The average time 
between HP and DM diagnosis was 80  ±  24  months 
(range: 60–180 months) (Table 1).
All patients used insulin. The mean dose was 
0.71 ± 0.63 IU/kg (range: 0.27–1.76 IU/kg). In 4 patients, 
other drugs (Metformin and Glyburide) were used before 
insulin therapy was started, mean time of 46 ± 45 months 
(range: 4–96 months).
The average CBG was 217.00  ±  69.44  mg/dl (range: 
145–306 mg/dl) with SD of 104.75 ± 15.56 mg/dl (range: 
94–127 mg/dl). There was a high variability of CBG in all 
cases, with frequent hypoglycemic events and hypergly-
cemic excursions. HbA1c levels demonstrated the het-
erogeneity between patients, but most patients showed 
elevated levels (Fig. 2).
The average diabetes duration was 
120.80  ±  80.32  months (range: 24–228  months). No 
ketoacidosis episodes occurred, although there were 
Table 1 Clinical features of pancreatogenic diabetes in affected patients
BMI body mass index, CBG capillary blood glucose, SD standard deviation
a Mean of 5 years, method high-performance liquid chromatography (HPLC)















1 8 53 19 25.4 184/94 0.3 7.6 No
2 5 36 13 21.7 233/104.4 0.83 11.6 Retinopathy
3 14 25 2 29.7 – 0.27 8.2 No
4 2 16 10 22.6 145/94.8 0.41 11.5 No













Fig. 1 Pedigree of the reported family demonstrating 5 members with diabetes (blue) and exocrine pancreatic dysfunction (red), 1 member with 
only exocrine pancreatic dysfunction, 2 members with acute pancreatitis (yellow) and 2 clinically unaffected mutation carrier. NN no mutation, NM 
heterozygous mutation
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episodes of hospitalization because of severe hypogly-
cemia. Surgical procedures were performed on patients 
4 and 5, respectively, for refractory pain and abdominal 
complication. Patients 2 and 5 presented microvascular 
lesions secondary to diabetes with nonproliferative dia-
betic retinopathy with macular edema and distal sym-
metrical sensorimotor polyneuropathy accompanied by 
autonomic neuropathy, respectively.
Discussion
In this study, we describe the glycemic pattern of five 
patients with diabetes secondary to a mutation in the 
PRSS1 gene, which leads to an increased autocatalytic 
conversion of trypsinogen to active trypsin, that results 
in autodigestion and damage to the acinar cells [5, 6].
Mutations in the PRSS1 gene (R122H, N29I, A16V, and 











































Fig. 2 a Capillary blood glucose (CBG) of the patient 4 in 2 weeks with high glycemic variability. b HbA1c measurements of patients with Heredi‑
tary Pancreatitis over 5 years
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of mutations in HP kindreds [7, 8], but other mutations 
have also been described (Fig. 3) [9–11].
A high rate of hypoglycemia and CBG variability was 
observed in these patients with diabetes secondary to HP. 
The marked glycemic lability is probably due not only to 
a continued loss of insulin secreting β-cells but also from 
counter regulatory glucagon secreting α-cells. Addition-
ally, nutrients malabsorption resulted in impaired incre-
tin secretion and thereby diminished insulin release. 
Moreover, the lack of other paracrine or endocrine fac-
tors secreted by the pancreatic cells may also contribute 
to this glycemic pattern [12].
Unlike type 1 DM, even with high glucose levels no 
patient developed ketoacidosis. The reasons that may 
warrant this is that the β-cell deficit is seldom absolute 
and it occurs concomitantly with the loss of α-cells [13].
All patients required insulin therapy, but the progres-
sion of the pancreatic endocrine failure was extremely 
variable. In some of the cases, insulin was necessary 
shortly after the diabetes diagnosis, while in others, oral 
drug therapy without insulin was possible for years.
Oral antidiabetic agents may be appropriate in early 
pancreatogenic diabetes (HbA1c  <  8.0%). Metformin 
should be the drug of first choice, in the absence of con-
traindications, especially if concomitant insulin resistance 
is evidenced, and if it is tolerated due to common gas-
trointestinal adverse effects and weight loss [14]. Besides 
that, it is possible that Metformin might reduce the risk of 
pancreatic cancer, and therefore would have a theoretical 
rationale in chronic pancreatitis [15]. Oral therapy with 
insulin secretagogues (sulfonylurea and glinides) may 
also be considered as second-line therapy, but should be 
Fig. 3 Schematic mechanism underling mutations‑associated pancreatitis. The PRSS1 (Cationic Trypsinogen) mutation leads to a gain‑of‑function 
with an increased conversion of intrapancreatic trypsinogen to trypsin. The SPINK1 (Serine Protease Inhibitor Kazal type 1) and CTRC (Chymotrypsin 
C) mutations lead to loss of defenses against the activation of trypsinogen. Mutations in CPA1 (carboxypeptidase A1) generate misfolded proteins 
leading to endoplasmic reticulum stress
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aware of hypoglycemia in patients with inconsistent meal 
ingestion [3]. Thiazolidinediones, incretin based therapies 
and SGLT2 inhibitors should be avoided because of side 
effects and lack of data in this context [3, 16].
In advanced pancreatogenic diabetes, insulin therapy is 
the preferred treatment, and especially during acute epi-
sodes of pancreatitis or hospitalized patients, and severe 
malnutrition patients in which the anabolic effects of 
insulin are desired. Patients should be treated using gen-
eral insulin dosing and regimen guidelines for type 1 dia-
betes [3, 16]. The patients studied used NPH and regular 
insulin because it is the first choice in the local healthcare 
public system. Despite the use of human insulin, glyce-
mic control was more unpredictable than expected with 
high glycemic variability. The insulin analogues or insu-
lin pump therapy are treatment options that may allow a 
more stable glycemic control.
Moreover, the islet autotransplant might be an option 
for patients with severe chronic pancreatitis, who have 
debilitating abdominal pain refractory to medical or 
endoscopic interventions and for which total pancreatec-
tomy is indicated [17, 18]. Patient 4 underwent pancrea-
tectomy and could have benefited from this therapy to 
preserve the function of the remaining β-cells.
In summary, these data indicate that DM second-
ary to HP presents clinical heterogeneity among 
patients, but with high glycemic variability and diffi-
cult management. Hence, molecular diagnosis should 
be performed in suspicious patients of HP because it 
allows the proper approach. Strategies to improve the 
glycemic control in affected patients should also be 
pursued.
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